The DOI matches its Crossref record; 612 of the 626 references it cites were found in a registry or an index.
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Abstract
Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses to prevent tissue damage and autoimmunity, are often exploited by cancer cells to avoid destruction. The discovery of checkpoint proteins like PD-1/PD-L1 and CTLA-4 was pivotal in developing cancer immunotherapy. Immune checkpoint inhibitors (ICIs) have shown great success, with FDA-approved drugs like PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab, Tremelimumab), alongside LAG-3 inhibitor Relatlimab. Research continues on new checkpoints like TIM-3, VISTA, B7-H3, BTLA, and TIGIT. Biomarkers like PDL-1 expression, tumor mutation burden, interferon-γ presence, microbiome composition, and extracellular matrix characteristics play a crucial role in predicting responses to immunotherapy with checkpoint inhibitors. Despite their effectiveness, not all patients experience the same level of benefit, and organ-specific immune-related adverse events (irAEs) such as rash or itching, colitis, diarrhea, hyperthyroidism, and hypothyroidism may occur. Given the rapid advancements in this field and the variability in patient outcomes, there is an urgent need for a comprehensive review that consolidates the latest findings on immune checkpoint inhibitors, covering their clinical status, biomarkers, resistance mechanisms, strategies to overcome resistance, and associated adverse effects. This review aims to fill this gap by providing an analysis of the current clinical status of ICIs, emerging biomarkers, mechanisms of resistance, strategies to enhance therapeutic efficacy, and assessment of adverse effects. This review is crucial to furthering our understanding of ICIs and optimizing their application in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–612 of 612
Chen, Y., Fu, J., Li, Z., Chen, Q., Zhang, J., Yang, Y., Yang, P., Wang, J., Liu, Z., Cao, Y., et al. (2022) · Cancer Cytopathology · doi:10.1002/cncy.22661 · Cited by 10
Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab
Talb, J., Kamga, P. T., Mayenga, M., Costantini, A., Julié, C., Duménil, C., Dumoulin, J., Ouaknine, J., Giraud, V., Dujon, C., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03206-4 · Cited by 8
The DPY30-H3K4me3 Axis-Mediated PD-L1 Expression in Melanoma
Zhang, Z., Han, Y., Sun, Q., Wang, Y., & Sun, L. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s377678 · Cited by 8
Hu, X., Guo, J., Shi, J., Li, D., Li, X., & Zhao, W. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02512-6 · Cited by 8
Hodi, F. S., Tawbi, H. A., Lipson, E. J., Schadendorf, D., Ascierto, P. A., Matamala, L., Gutiérrez, E. C., Rutkowski, P. L., Gogas, H. J., Lao, C. D., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1421 · Cited by 8
Adding to the checkpoint blockade armamentarium
Hellmann, M. D., & Snyder, A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0350-5 · Cited by 6
Pant, S., Mulder, I. E., Shah, A. Y., Msaouel, P., Altan, M., Weinberg, J. D., Stevenson, A., Meric‐Bernstam, F., Yap, T. A., Subbiah, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps2670 · Cited by 6
MSI-H/dMMR and cancer immunotherapy: current state and future implications
Rizzo, A., Ricci, A. D., & Gadaleta‐Caldarola, G. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1946391 · Cited by 5
Identification, characterization, expression profiles of OlHavcr2 in medaka (Oryzias latipes)
Nibona, E., Xu, G., Wu, K., Shen, H., Zhang, R., Ke, X., Hafiz, A. A., Wang, Z., Qi, C., & Zhao, H. (2018) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2018.10.023 · Cited by 5
Gomez‐Roca, C., Champiat, S., Cassier, P. A., Jegou, D., Primard, M., Pétain, A., Gueguen‐Dorbes, G., Fabre, C., Melero, I., & Marabelle, A. (2024) · Cancer Research · doi:10.1158/1538-7445.am2024-ct181 · Cited by 5
Tumor Evasion of Immune System
Ruiz-Cabello, F., & Garrido, F. (2002) · CRC Press eBooks · doi:10.1201/b12622-13 · Cited by 2
Kamga, P. T., Swalduz, A., Costantini, A., Julié, C., Emile, J., Pérol, M., Avrillon, V., Ortiz‐Cuaran, S., Saintigny, P., & Leprieur, E. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852540 · Cited by 1
Cited by
The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances
Chen, H., Yang, H., Guo, L., & Sun, Q. (2025) · MedComm · doi:10.1002/mco2.70412 · Cited by 66
Li, J., Peng, J., Wang, J., & Chen, Z. (2025) · Med Research · doi:10.1002/mdr2.70022 · Cited by 62
Han, X., Zhang, J., Li, W., Huang, X., Wang, X., Wang, B., Gao, L., & Chen, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1512509 · Cited by 55
Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 34
Dendritic cell immunotherapy advances for solid tumors: Vaccination and modulation
Clayton, G., Toffoli, E. C., de Gruijl, T. D., & van Kooyk, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102412 · Cited by 30
Metadata
- Authors
- Arafat Hossain, M.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 143
- Issue
- Pt 2
- Pages
- 113365
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W4403679157
- Cited by
- 178
- References
- 626
- FWCI
- 27.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.